Inozyme Pharma to Present at the Jefferies Global Healthcare Conference
30 May 2024 - 10:30PM
Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a
clinical-stage rare disease biopharmaceutical company developing
novel therapeutics for the treatment of pathologic mineralization
and intimal proliferation, today announced Doug Treco, Ph.D., CEO
and Chairman of Inozyme, will present at the Jefferies Global
Healthcare Conference on Thursday, June 6, 2024 from 12:30-12:55 pm
ET.
A live webcast of the presentation can be
accessed from the Investor Relations section of Inozyme’s
website under events, where a replay of the event will also be
available for a limited time.
About Inozyme Pharma
Inozyme Pharma, Inc. is a clinical-stage rare
disease biopharmaceutical company developing novel therapeutics for
the treatment of diseases impacting the vasculature, soft tissue,
and skeleton. Inozyme is developing INZ-701, an enzyme replacement
therapy, to address pathologic mineralization and intimal
proliferation, which can drive morbidity and mortality in these
severe diseases. INZ-701 is currently in clinical development for
the treatment of ENPP1 Deficiency, ABCC6 Deficiency and
calciphylaxis.
For more information, please
visit https://www.inozyme.com/ or follow Inozyme
on LinkedIn, X, and Facebook.
Contacts
Investors:Inozyme PharmaStefan Riley, Senior Director of IR and
Corporate Communications(857) 330-8871stefan.riley@inozyme.com
Media: SmithSolve Matt Pera(973)
886-9150matt.pera@smithsolve.com
Inozyme Pharma (NASDAQ:INZY)
Historical Stock Chart
From May 2024 to Jun 2024
Inozyme Pharma (NASDAQ:INZY)
Historical Stock Chart
From Jun 2023 to Jun 2024